{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-144484","form_type":"8-K","ticker":"CRNX","cik":"0001658247","company_name":"Crinetics Pharmaceuticals, Inc.","filed_at":"2024-05-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.464443+00:00","generated_at":"2026-06-01T09:46:39.105967+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"medium","headline":"Crinetics announces early release of ENDO 2024 late-breaking abstracts for atumelnant Phase 2 CAH study","bullets":["Late-breaking abstracts for atumelnant (CRN04894) Phase 2 CAH study released before embargo.","Abstract contained summary data on 4 subjects; data from 6 subjects in cohort 1 and cohort 2 to be presented June 3, 2024.","Full data set will be presented at ENDO 2024 poster session on June 1-2 pm ET."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-144484","json":"https://secwatch.observer/filing/0001193125-24-144484.json","markdown":"https://secwatch.observer/filing/0001193125-24-144484.md","text":"https://secwatch.observer/filing/0001193125-24-144484.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658247/000119312524144484/0001193125-24-144484-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658247/000119312524144484/d815433d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T09:46:39.105967+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}